<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01977300</url>
  </required_header>
  <id_info>
    <org_study_id>H02-70188</org_study_id>
    <secondary_id>V02-0130</secondary_id>
    <nct_id>NCT01977300</nct_id>
  </id_info>
  <brief_title>Atypical Antipsychotics for Continuation and Maintenance Treatment After an Acute Manic Episode</brief_title>
  <official_title>Atypical Antipsychotics for Continuation and Maintenance Treatment After an Acute Manic Episode</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Janssen-Ortho Inc., Canada</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of British Columbia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypothesis: Continuation of an atypical antipsychotic medication in combination with a Mood
      Stabilizer, following remission from an acute manic episode, lowers the rates of relapse and
      recurrence of mood episodes compared to discontinuing the antipsychotics within days of
      resolution of manic symptoms.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomised, double-blind, placebo controlled trial over 52 weeks. Patients will be
      on one of four combinations of medications at the time of entry into the study: a) lithium
      and risperidone, b) lithium and olanzapine, c) valproate and risperidone, or d) valproate and
      olanzapine. After obtaining informed consent, patients will be randomised to one of three
      groups 1)&quot;0&quot; week group: patients will receive lithium or valproate plus placebo for 52 weeks
      (risperidone or olanzapine tapering will begin on the day of randomisation with
      discontinuation of the drug within 2 weeks), 2) continuation of the same atypical
      antipsychotic, risperidone or olanzapine, plus lithium or valproate for 24 weeks (tapering of
      the antipsychotic begins at the end of 24 weeks and completed within 2 weeks) followed by the
      same mood stabilizer plus placebo for another 28 weeks, and 3) continuation of the atypical
      antipsychotic, risperidone or olanzapine, plus lithium or valproate for 52 weeks. The
      duration of the double-blind phase of the study will be 52 weeks and all patients will
      continue on the mood stabilizer, lithium or valproate, they had been on during the acute
      mania for the full duration of the study. The serum level of the mood stabilizer will be
      maintained within the therapeutic range (0.6 to 1.2 mmol/L for lithium and 50 to 125 ug/L for
      valproate) throughout the 52 weeks as determined by blood tests. The dose and the type of
      atypical antipsychotic (ie risperidone or olanzapine) each patient will receive during the
      double-blind period will be the same that the patient had been on at the time of entry into
      the double-blind phase. All patients, irrespective of which treatment arm they are in, will
      receive active psychoeducation and counselling regarding sleep hygiene, healthy daily
      routines and rhythms, alcohol and substance abuse, anxiety management, conflict resolution
      and problem solving as clinically indicated in routine clinical practice. Patients who
      withdraw from or meet a primary end point of the study will be treated actively as done in
      regular clinical practice.

      Patients will not be allowed to receive any other psychotropic medication with the exception
      of benzodiazepines for sedation and anti-parkinsonian medication for extrapyramidal side
      effects. The doses of these will be recorded.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2003</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcome measure is the time to any mood episode (depressive or manic episode).</measure>
    <time_frame>52 weeks</time_frame>
    <description>A mood episode is defined as 1) Young Mania Rating Scale (YMRS) score of 15 or greater 2)Hamilton Rating Scale for Depression (HAM-D) 21-item score of 15 or greater or a HAM-D suicide item score of 3 or greater 3)A Clinical Global Impression -Severity (CGI-S) score of 3 or greater 4) a patient requiring hospitalization for treatment of mood symptoms or 5) a patient who makes a suicide attempt or commits suicide during the study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to manic episode.</measure>
    <time_frame>52 weeks</time_frame>
    <description>Time to occurrence of a manic episode measured by Young Mania Rating Scale (YMRS) score of 15 or greater .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to depressive episode</measure>
    <time_frame>52 weeks</time_frame>
    <description>Time to occurrence of a depressive episode measured by Hamilton Rating Scale for Depression (HAM-D) 21-item score of 15 or greater or a HAM-D suicide item score of 3 or greater.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">159</enrollment>
  <condition>Bipolar I Disorder</condition>
  <arm_group>
    <arm_group_label>Mood stabilizer &amp; Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will receive lithium or valproate plus placebo for 52 weeks (risperidone or olanzapine tapering will begin on the day of randomization with discontinuation of the drug within 2 weeks).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>'24 week &quot; arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Continuation of the lithium or valproate plus risperidone or olanzapine for 24 weeks followed by mood stabilizer plus placebo for another 28 weeks. Dosages: 1 to 6 mg of risperidone, 5 to 20 mg olanzapine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>&quot;52 week&quot; arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Continuation of the atypical antipsychotic, risperidone or olanzapine, plus lithium or valproate for 52 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valproate</intervention_name>
    <description>serum level of 50 to 125 ug/L</description>
    <arm_group_label>Mood stabilizer &amp; Placebo</arm_group_label>
    <arm_group_label>'24 week &quot; arm</arm_group_label>
    <arm_group_label>&quot;52 week&quot; arm</arm_group_label>
    <other_name>Valproic Acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lithium</intervention_name>
    <description>serum levels of 0.6 to 1.2 mmol/L</description>
    <arm_group_label>Mood stabilizer &amp; Placebo</arm_group_label>
    <arm_group_label>'24 week &quot; arm</arm_group_label>
    <arm_group_label>&quot;52 week&quot; arm</arm_group_label>
    <other_name>Lithium Carbonate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Risperidone</intervention_name>
    <description>1 to 6 mg/day</description>
    <arm_group_label>'24 week &quot; arm</arm_group_label>
    <arm_group_label>&quot;52 week&quot; arm</arm_group_label>
    <other_name>Risperdal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olanzapine</intervention_name>
    <description>5 to 25 mg/day</description>
    <arm_group_label>'24 week &quot; arm</arm_group_label>
    <arm_group_label>&quot;52 week&quot; arm</arm_group_label>
    <other_name>Zyprexa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>manufactured to mimic risperidone and olanzapine</description>
    <arm_group_label>Mood stabilizer &amp; Placebo</arm_group_label>
    <arm_group_label>'24 week &quot; arm</arm_group_label>
    <other_name>Sugar Pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who were recently (within the last 12 weeks) commenced on treatment for a
             Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) manic or mixed episode
             with a combination of lithium and risperidone, lithium and olanzapine, valproate and
             risperidone, or valproate and olanzapine;

          -  Patients on 1 to 6 mg of risperidone or 5 to 25 mg of olanzapine

          -  Patients who are in remission from mania for at least 2 weeks but no more than 6 weeks
             and have maintained remission for 2 consecutive weeks;

          -  Patients must not be taking any other psychotropic medication (with the exception of
             benzodiazepines) or treatments including bromocriptine, omega 3 fatty acids, Axid or
             EMPower;

          -  Patients aged 17 and above.

        Exclusion Criteria:

          -  Any subjects who do not meet the above inclusion criteria will be excluded from the
             study.

          -  In order for the findings to be generalizable to clinically representative patients
             with bipolar disorder, any patients with a history of co-morbid substance abuse or
             medical illnesses will not be excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>17 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lakshmi N Yatham, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of British Columbia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Serge Beaulieu, Dr.</last_name>
    <role>Study Director</role>
    <affiliation>McGill University, Montreal</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andree Daigneault, Dr.</last_name>
    <role>Study Director</role>
    <affiliation>Clinique des Maladies Affectives, Montreal</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Verinder Sharma, Dr.</last_name>
    <role>Study Director</role>
    <affiliation>Regional Mental Health Care London, Ont.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hubert Wong, Dr.</last_name>
    <role>Study Director</role>
    <affiliation>University of British Columbia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ayal Schaffer, Dr.</last_name>
    <role>Study Director</role>
    <affiliation>Sunnybrook Health Sciences Centre, Toronto, Ont.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sagar Parikh, Dr.</last_name>
    <role>Study Director</role>
    <affiliation>Centre for Addiction and Mental Health, Toronto, Ont.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Philippe Baruch, Dr.</last_name>
    <role>Study Director</role>
    <affiliation>Clinique des troubles de l'humeur, Quebec</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter Silverstone, Dr.</last_name>
    <role>Study Director</role>
    <affiliation>University of Alberta</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Roumen Milev, Dr.</last_name>
    <role>Study Director</role>
    <affiliation>Providence Continuing Care, Kingston, Ont.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ram Veluri, Dr.</last_name>
    <role>Study Director</role>
    <affiliation>Northern Health Research Inc., Sudbury, Ont.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pablo Cervantes, Dr.</last_name>
    <role>Study Director</role>
    <affiliation>Montreal General, Quebec</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Claire O'Donovan, Dr.</last_name>
    <role>Study Director</role>
    <affiliation>Mental Health Services, Halifax, NS</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Flavio Kapczinski, Dr.</last_name>
    <role>Study Director</role>
    <affiliation>Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Benny Lafer, Dr.</last_name>
    <role>Study Director</role>
    <affiliation>Instituto de Psiquiatria do Hospital das Clínicas, Sao Paulo, Brazil</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Angelo B Miralha da Cunha, Dr.</last_name>
    <role>Study Director</role>
    <affiliation>Santa Maria, Brazil</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joao Quevedo, Dr.</last_name>
    <role>Study Director</role>
    <affiliation>Casa de Saude do Rio Maina Ltda, Criciuma, Brazil</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of British Columbia</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6T 2A1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Yatham LN, Beaulieu S, Schaffer A, Kauer-Sant'Anna M, Kapczinski F, Lafer B, Sharma V, Parikh SV, Daigneault A, Qian H, Bond DJ, Silverstone PH, Walji N, Milev R, Baruch P, da Cunha A, Quevedo J, Dias R, Kunz M, Young LT, Lam RW, Wong H. Optimal duration of risperidone or olanzapine adjunctive therapy to mood stabilizer following remission of a manic episode: A CANMAT randomized double-blind trial. Mol Psychiatry. 2016 Aug;21(8):1050-6. doi: 10.1038/mp.2015.158. Epub 2015 Oct 13.</citation>
    <PMID>26460229</PMID>
  </reference>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 22, 2013</study_first_submitted>
  <study_first_submitted_qc>October 30, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 6, 2013</study_first_posted>
  <last_update_submitted>November 19, 2015</last_update_submitted>
  <last_update_submitted_qc>November 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 20, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Risperidone</mesh_term>
    <mesh_term>Antipsychotic Agents</mesh_term>
    <mesh_term>Olanzapine</mesh_term>
    <mesh_term>Lithium Carbonate</mesh_term>
    <mesh_term>Valproic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

